Robotic surgery in ovarian cancer

Best Pract Res Clin Obstet Gynaecol. 2023 Aug:90:102391. doi: 10.1016/j.bpobgyn.2023.102391. Epub 2023 Jul 12.

Abstract

Ovarian cancer (OC) represents one of the most lethal cancers in women. The aim of surgical treatment is complete cytoreduction in advanced stages and a surgical staging in early stages. Although the guidelines still suggest laparotomy as the standard approach, in recent years minimally invasive surgery (MIS) has become increasingly popular in the treatment of OC, especially in early stages, because the 5-year relative survival exceeds 90% and the patients' quality of life cannot be overshadowed. However, MIS has been demonstrated to have a role even in advanced stages, in the prediction of optimal cytoreduction, identification patients who may benefit from neoadjuvant chemotherapy, and, more recently, in the interval debulking surgery, as in selected cases of secondary cytoreduction for recurrent ovarian cancer. The aim of this review is to describe the MIS (especially robotic surgery), with its advantages and pitfalls, in the treatment of OC.

Keywords: Minimally invasive surgery; Ovarian cancer; Robotic surgery.

Publication types

  • Review

MeSH terms

  • Carcinoma, Ovarian Epithelial / surgery
  • Chemotherapy, Adjuvant
  • Cytoreduction Surgical Procedures
  • Female
  • Humans
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / surgery
  • Neoplasm Staging
  • Ovarian Neoplasms* / pathology
  • Quality of Life
  • Robotic Surgical Procedures*